Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "quarterly-earnings"

3 News Found

Supriya Lifescience posts 50% revenue growth in Q4 FY26; PAT rises to Rs 74 crore
News | May 28, 2026

Supriya Lifescience posts 50% revenue growth in Q4 FY26; PAT rises to Rs 74 crore

On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25

JB Chemicals reports muted Q4 FY26 as integration resets business
News | May 12, 2026

JB Chemicals reports muted Q4 FY26 as integration resets business

The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year

Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
News | November 07, 2025

Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3

Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Merck names Miguel Alcalde to lead global commercial strategy; Monia Vial to head North America

Merck wins EU nod for KEYTRUDA-Padcev regimen in muscle-invasive bladder cancer

Reliance-backed Karkinos Healthcare crosses 1 lakh cervical cancer screening in India

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Peptides are next frontline therapeutics led by GLP-1: Dr. Vandana Singh, Head - API Regulatory Sciences, Biocon Limited
Peptides are next frontline therapeutics led by GLP-1: Dr. Vandana Singh, Head - API Regulatory Sciences, Biocon Limited
Rising pharma demand driving our India market strategy: Sanjeev Kumar Khandelwal, Head of Division, Characterization Division, Anton Paar India
Rising pharma demand driving our India market strategy: Sanjeev Kumar Khandelwal, Head of Division, Characterization Division, Anton Paar India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International

Packaging